Nektar Therapeutics (NASDAQ:NKTR) is scheduled to be announcing its earnings results after the market closes on Thursday, March 1st. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.
Nektar Therapeutics (NASDAQ NKTR) opened at $90.56 on Tuesday. The company has a market cap of $14,260.00, a PE ratio of -127.55 and a beta of 2.04. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14. Nektar Therapeutics has a 52 week low of $12.50 and a 52 week high of $99.02.
In other news, CAO Jillian B. Thomsen sold 2,545 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $211,082.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Stephen K. Doberstein sold 2,426 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $201,212.44. Following the transaction, the senior vice president now owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 222,781 shares of company stock valued at $14,884,901. Insiders own 5.44% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.